Search Results - "Boyer, Serge"

Refine Results
  1. 1
  2. 2
  3. 3

    Selection of QPX7831, an Orally Bioavailable Prodrug of Boronic Acid β‑Lactamase Inhibitor QPX7728 by Reddy, K. Raja, Parkinson, Jonathan, Sabet, Mojgan, Tarazi, Ziad, Boyer, Serge H, Lomovskaya, Olga, Griffith, David C, Hecker, Scott J, Dudley, Michael N

    Published in Journal of medicinal chemistry (09-12-2021)
    “…In recognition of the need for effective oral therapies to treat Gram-negative bacterial infections, efforts were directed toward identifying an oral prodrug…”
    Get full text
    Journal Article
  4. 4
  5. 5
  6. 6
  7. 7

    Scalable On-Demand Production of Purified Diazomethane Suitable for Sensitive Catalytic Reactions by Sheeran, Jillian W, Campbell, Kiersten, Breen, Christopher P, Hummel, Gerald, Huang, Changfeng, Datta, Anamika, Boyer, Serge H, Hecker, Scott J, Bio, Matthew M, Fang, Yuan-Qing, Ford, David D, Russell, M. Grace

    Published in Organic process research & development (19-03-2021)
    “…We have developed a convenient development-scale reactor (0.44 mol/h) to prepare diazomethane from N-methyl-N-nitroso-p-toluenesulfonamide (MNTS) in ∼80%…”
    Get full text
    Journal Article
  8. 8

    Pradefovir: A Prodrug That Targets Adefovir to the Liver for the Treatment of Hepatitis B by Reddy, K. Raja, Matelich, Michael C, Ugarkar, Bheemarao G, Gómez-Galeno, Jorge E, DaRe, Jay, Ollis, Kristin, Sun, Zhili, Craigo, William, Colby, Timothy J, Fujitaki, James M, Boyer, Serge H, van Poelje, Paul D, Erion, Mark D

    Published in Journal of medicinal chemistry (14-02-2008)
    “…Adefovir dipivoxil, a marketed drug for the treatment of hepatitis B, is dosed at submaximally efficacious doses because of renal toxicity. In an effort to…”
    Get full text
    Journal Article
  9. 9
  10. 10

    A Potent and Selective AMPK Activator That Inhibits de Novo Lipogenesis by Gómez-Galeno, Jorge E, Dang, Qun, Nguyen, Thanh H, Boyer, Serge H, Grote, Matthew P, Sun, Zhili, Chen, Mingwei, Craigo, William A, van Poelje, Paul D, MacKenna, Deidre A, Cable, Edward E, Rolzin, Paul A, Finn, Patricia D, Chi, Bert, Linemeyer, David L, Hecker, Scott J, Erion, Mark D

    Published in ACS medicinal chemistry letters (09-12-2010)
    “…AMP-activated protein kinase (AMPK) is a heterotrimeric kinase that regulates cellular energy metabolism by affecting energy-consuming pathways such as de novo…”
    Get full text
    Journal Article
  11. 11
  12. 12
  13. 13

    Liver-Targeted Prodrugs of 2‘-C-Methyladenosine for Therapy of Hepatitis C Virus Infection by Hecker, Scott J, Reddy, K. Raja, van Poelje, Paul D, Sun, Zhili, Huang, Wenjian, Varkhedkar, Vaibhav, Reddy, M. Venkat, Fujitaki, James M, Olsen, David B, Koeplinger, Kenneth A, Boyer, Serge H, Linemeyer, David L, MacCoss, Malcolm, Erion, Mark D

    Published in Journal of medicinal chemistry (09-08-2007)
    “…2‘-C-Methyladenosine exhibits impressive inhibitory activity in the cell-based hepatitis C virus (HCV) subgenomic replicon assay, by virtue of intracellular…”
    Get full text
    Journal Article
  14. 14

    Delivery of high levels of anti-proliferative nucleoside triphosphates to CYP3A-expressing cells as a potential treatment for hepatocellular carcinoma by MacKenna, Deidre A, Montag, Annika, Boyer, Serge H, Linemeyer, David L, Erion, Mark D

    Published in Cancer chemotherapy and pharmacology (01-10-2009)
    “…Purpose Hepatocellular carcinoma (HCC) is a life-threatening condition with only one drug treatment regimen approved for use. Oncolytic nucleosides are…”
    Get full text
    Journal Article
  15. 15
  16. 16
  17. 17

    Stereoselective synthesis of 4- C-methyl-2,3,5-tri- O-benzyl- d-ribofuranose and 4- C-methyl-2,3,5-tri- O-benzyl- l-lyxofuranose by Boyer, Serge H, Ugarkar, Bheemarao G, Erion, Mark D

    Published in Tetrahedron letters (19-05-2003)
    “…Sugar intermediates 4- C-methyl-2,3,5-tri- O-benzyl- d-ribofuranose ( 8b ) and 4- C-methyl-2,3,5-tri- O-benzyl- l-lyxofuranose ( 8a ) were synthesized by…”
    Get full text
    Journal Article
  18. 18

    Specific Inhibition of Formation of Transcription Complexes by a Calicheamicin Oligosaccharide: A Paradigm for the Development of Transcriptional Antagonists by Ho, Steffan N., Boyer, Serge H., Schreiber, Stuart L., Danishefsky, Samuel J., Crabtree, Gerald R.

    “…Sequence-specific DNA ligands that antagonize DNA-protein interactions represent a potentially powerful means of modulating gene expression. Calicheamicin γ1…”
    Get full text
    Journal Article
  19. 19
  20. 20

    Interaction of calicheamicin γ1I and its related carbohydrates with DNA–protein complexes by Sissi, Claudia, Aiyar, Jayshree, Boyer, Serge, Depew, Kris, Danishefsky, Samuel, Crothers, Donald M.

    “…We report studies of the contribution of DNA structure, holding the sequence constant, to the affinity of calicheamicin γ 1 I and its aryltetrasaccharide…”
    Get full text
    Journal Article